PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Hayes Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ancient Herb is Key in Hoodia Weight Loss Approach Says DMDpharm.com - Success is possible with DMD Pharmaceuticals' Hoodia weight loss solution. Providing extra willpower in the form of an appetite suppressant, this Hoodia diet supplement is designed for fast weight loss
Ancient Herb is Key in Hoodia Weight Loss Approach Says DMDpharm.com

 

NewswireToday - /newswire/ - Indianapolis, IN, United States, 2006/08/17 - Success is possible with DMD Pharmaceuticals' Hoodia weight loss solution. Providing extra willpower in the form of an appetite suppressant, this Hoodia diet supplement is designed for fast weight loss.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DMD Pharmaceuticals announces its new Hoodia Gordonii diet pill, Trim-U™, which has been formulated to help dieters reach their optimum weight loss goals quickly. Both an appetite suppressant and energizer, the Trim-U™ Hoodia diet supplement contains 250 mg of Hoodia Gordonii, the renowned ancient appetite suppressant.

The Trim-U™ with Hoodia weight loss pill also contains 10 mg of Garcinia Cambogia extract, which is beneficial to dieters due to its effects in metabolizing carbohydrates. By combining the properties of Garcinia Cambogia and Hoodia, this diet supplement offers a serious weight loss method. In addition, Trim-U's ingredients also include green tea and pharmaceutical-grade caffeine, giving dieters the energy boost they need.

"Taken as part of a complete weight loss program, Trim-U™ Hoodia Gordonii diet pill is the ideal first step. Our Hoodia diet supplement can fortify the willpower to help you start loosing pounds," states Dave Riddle of DMD Pharmaceuticals. "Once the weight starts coming off, dieters will be able to realize the incentive in continuing with a sensible diet and moderate exercise program to sustain their weight loss efforts."

The best thing about the Trim-U™ Hoodia weight loss method is that it does not require long-term usage of the product. Balanced and nutritious meals combined with the proper exercise can do the rest. Of course, the Hoodia diet supplement can be used when needed, when energy levels needs a boost or when temptation at the buffet table seems overwhelming.

Available without a prescription, DMD's Trim-U™ Hoodia weight loss product is available in many drug and convenience stores, as well as online at their website.

About DMD Pharma
DMD (dmdpharm.com) is one of the leading marketers of over-the-counter pharmaceuticals and dietary supplements with distribution in over 50,000 convenience stores nationwide. The Peptime® family of energizers and other leading DMD dietary supplement brands include Ephrine Plus® High Energy, Ultra Ephrine Plus®, and Ginseng Vita Blitz®.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Hayes Group

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ancient Herb is Key in Hoodia Weight Loss Approach Says DMDpharm.com

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dave Riddle - DMDpharm.com 
1-800-795-2477 distributions[.]dmdpharm.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Hayes Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Hayes Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)